Hanahan and Weinberg have proposed the ‘hallmarks of cancer’ to cover the biological changes required for the development and persistence of tumours [Hanahan and Weinberg (2011) Cell 144, 646–674]. We have noted that many of these cancer hallmarks are facilitated by the multifunctional protein YB-1 (Y-box-binding protein 1). In the present review we evaluate the literature and show how YB-1 modulates/regulates cellular signalling pathways within each of these hallmarks. For example, we describe how YB-1 regulates multiple proliferation pathways, overrides cell-cycle check points, promotes replicative immortality and genomic instability, may regulate angiogenesis, has a role in invasion and metastasis, and promotes inflammation. We also argue that there is strong and sufficient evidence to suggest that YB-1 is an excellent molecular marker of cancer progression that could be used in the clinic, and that YB-1 could be a useful target for cancer therapy.
Skip Nav Destination
Article navigation
January 2013
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Review Article|
December 07 2012
YB-1: oncoprotein, prognostic marker and therapeutic target?
Annette Lasham;
Annette Lasham
1
*Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
1To whom correspondence should be addressed (email a.lasham@auckland.ac.nz).
Search for other works by this author on:
Cristin G. Print;
Cristin G. Print
*Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
†Bioinformatics Institute, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Search for other works by this author on:
Adele G. Woolley;
Adele G. Woolley
‡Department of Pathology, School of Medicine, University of Otago, PO Box 913, Dunedin, 9054, New Zealand
Search for other works by this author on:
Sandra E. Dunn;
Sandra E. Dunn
§Department of Paediatrics and Experimental Medicine, University of British Columbia, Vancouver, 950W 28th Ave, BC V5Z 4H4, Canada
Search for other works by this author on:
Antony W. Braithwaite
Antony W. Braithwaite
‡Department of Pathology, School of Medicine, University of Otago, PO Box 913, Dunedin, 9054, New Zealand
¶Children's Medical Research Institute, University of Sydney, Locked Bag 23, Wentworthville, NSW 2145, Australia
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
August 21 2012
Revision Received:
October 02 2012
Accepted:
October 09 2012
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© The Authors Journal compilation © 2013 Biochemical Society
2013
Biochem J (2013) 449 (1): 11–23.
Article history
Received:
August 21 2012
Revision Received:
October 02 2012
Accepted:
October 09 2012
Citation
Annette Lasham, Cristin G. Print, Adele G. Woolley, Sandra E. Dunn, Antony W. Braithwaite; YB-1: oncoprotein, prognostic marker and therapeutic target?. Biochem J 1 January 2013; 449 (1): 11–23. doi: https://doi.org/10.1042/BJ20121323
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.